The best indicator for Novo Nordisk
We backtested 382 indicators across daily, weekly and hourly charts on real Novo Nordisk history. Here's what actually worked — risk-adjusted over the full backtest, with costs, and checked out-of-sample.
Where Novo Nordisk stands
Computed from our own daily OHLCV history, not quoted from a third party. Moving averages use closing prices; "52-week" is the last 252 trading sessions.
EMA 13/48 Cross
On the weekly chart, this is the strongest risk-adjusted edge we found for Novo Nordisk over ~45.6 years — beating buy-and-hold by 1.6% CAGR.
Novo Nordisk on the weekly chart
The timeframe our backtest found best for this asset. The chart is live market data; the results above are hypothetical and historical.
Chart by TradingView. Loading it contacts tradingview.com, which may set its own cookies — see our privacy policy.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 13/48 Cross ✓ | Weekly | 16.0% | 0.78 | -33.7% | 73.3% | 15 | 1.6% |
| 2 | Guppy Multiple MA ✓ | Weekly | 14.9% | 0.74 | -43.0% | 65.2% | 23 | 0.6% |
| 3 | WMA 15/60 Cross ✓ | Weekly | 14.9% | 0.74 | -39.8% | 76.2% | 21 | 0.5% |
| 4 | SMA 50/200 Cross ✓ | Daily | 14.8% | 0.73 | -39.9% | 61.5% | 26 | 0.3% |
| 5 | SMA 15/60 Cross ✓ | Weekly | 14.6% | 0.73 | -39.3% | 81.2% | 16 | 0.2% |
| 6 | WMA 20/80 Cross ✓ | Weekly | 14.5% | 0.73 | -43.4% | 68.8% | 16 | 0.1% |
| 7 | T3 10/40 Cross ✓ | Weekly | 13.3% | 0.73 | -35.1% | 71.4% | 21 | -1.1% |
| 8 | EMA 50/200 Cross ✓ | Daily | 14.8% | 0.72 | -45.2% | 61.9% | 21 | 0.3% |
| 9 | WMA 20/50 Cross ✓ | Weekly | 13.8% | 0.71 | -43.0% | 57.7% | 26 | -0.6% |
| 10 | EMA 9/26 Cross ✓ | Weekly | 14.1% | 0.71 | -38.5% | 57.6% | 33 | -0.3% |
| 11 | EMA 10/40 Cross ✓ | Weekly | 14.2% | 0.71 | -41.2% | 69.6% | 23 | -0.2% |
| 12 | TRIX (15) ✓ | Weekly | 14.1% | 0.71 | -55.6% | 68.2% | 22 | -0.2% |
| 13 | Supertrend (20,3) ✓ | Weekly | 13.7% | 0.71 | -37.4% | 76.7% | 30 | -0.7% |
| 14 | SMC: Change of Character ✓ | Weekly | 13.8% | 0.71 | -50.4% | 70.0% | 20 | -0.6% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
What it would take to beat buy & hold on Novo Nordisk
39 of 689 tested setups beat buy-and-hold on Novo Nordisk outright. Another 161 could get there with leverage they would survive — but 319 would be liquidated by their own drawdown before they caught it.
| Indicator | Beats B&H unlevered | Leverage needed | Leverage survived |
|---|---|---|---|
| Zero-Lag MACD | 2 | none needed | 2.22× |
| Detrended Price Osc. | 1 | 1.38× | 1.81× |
| WMA 10/40 Cross | 1 | 1.58× | 2.74× |
| Fisher Center-of-Gravity | 1 | 1.6× | 2.67× |
| SMA 100 Trend | 1 | 1.76× | 2.6× |
| WMA 20/50 Cross | 1 | 1.88× | 2.9× |
Out-of-sample, costs included. A setup is only listed if the leverage it needs is less than the leverage its own worst drawdown survives — when it isn't, no amount of leverage gets there. Volatility drag isn't modelled, so these are the optimistic case. Every indicator, ranked this way
For Novo Nordisk, EMA 13/48 Cross on the weekly timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get alerted when Novo Nordisk’s signal flips
We track Novo Nordisk daily. Its backtested best indicator, EMA 13/48 Cross (Weekly), is flat right now — we'll email you the moment that changes. Free, no spam, unsubscribe any time.